Why the study?
Do serum neutralizing antibody titers correlate with serotype-specific protection against clinically significant rotavirus diarrhea in children?
Do serum neutralizing antibody titers correlate with serotype-specific protection against clinically significant rotavirus diarrhea in children?
Protection against rotavirus diarrhea after natural infection correlates with heterotypic neutralizing antibody titers, suggesting immunity may not be strictly serotype-specific.
Answers are grounded in this paper and cite their sources.
Heterotypic titers may inform broader rotavirus vaccine design; leaves open whether serotype-specific immunity is required.
This case-control study sought to determine whether protection against clinically significant rotavirus diarrhea in children aged 4-35 months correlated with titers of serum neutralizing antibody and, if so, whether this protection was serotype-specific. Titers of acute-phase sera from 156 cases of treated rotavirus diarrhea in rural Bangladesh were contrasted with titers from 312 contemporaneously selected, age-matched controls. Analyses of the culture-adapted rotaviruses from the cases revealed that 24%, 15%, 43%, and 17% belonged to serotypes 1-4, respectively. Titers of both homologous and heterologous neutralizing antibody in acute blood specimens of cases were significantly lower than those of matched controls. However, multivariate logistic regression models demonstrated that only antibody titers to heterotypic rotaviruses were independently associated with protection against rotavirus disease. These data, which indicate that the correlation of protection with neutralizing antibody titers is not serotype-specific, suggest that immunity to rotavirus disease may be mediated by other factors.
No takes yet. Share an insight, caveat, or question.
Ward et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: